Artificial Intelligence Reveals Distinct Prognostic Subgroups of Muscle-Invasive Bladder Cancer on Histology Images
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Cancers 15 (2023) 20, 4998, 1-22
- Ereignis
-
Veröffentlichung
- (wo)
-
Münster
- (wer)
-
Universitäts- und Landesbibliothek Münster
- (wann)
-
2023
- Urheber
- DOI
-
10.17879/78978584207
- URN
-
urn:nbn:de:hbz:6-78978581382
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Eminaga, Okyaz
- Leyh-Bannurah, Sami-Ramzi
- Shariat, Shahrokh F.
- Krabbe, Laura-Maria
- Lau, Hubert
- Xing, Lei
- Abbas, Mahmoud
- Universitäts- und Landesbibliothek Münster
Entstanden
- 2023
Ähnliche Objekte (12)
Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer
Prostatakrebs : Vorbeugung, Diagnose; Therapie
Medical practice and placebo response: an inseparable bond?
Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?
PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients : Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer
ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?
Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer
Molecular markers in bladder cancer
Focal therapy in intermediate- and high-risk prostate cancer
Neoadjuvant therapy in urothelial cancer : New therapies on the horizon
Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers
AI allows pre-screening of FGFR3 mutational status using routine histology slides of muscle-invasive bladder cancer
Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer
Prostatakrebs : Vorbeugung, Diagnose; Therapie
Medical practice and placebo response: an inseparable bond?
Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?
PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients : Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer
ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?
Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer
Molecular markers in bladder cancer
Focal therapy in intermediate- and high-risk prostate cancer
Neoadjuvant therapy in urothelial cancer : New therapies on the horizon
Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers
AI allows pre-screening of FGFR3 mutational status using routine histology slides of muscle-invasive bladder cancer
Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer
Prostatakrebs : Vorbeugung, Diagnose; Therapie
Medical practice and placebo response: an inseparable bond?
Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?
PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients : Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer
ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?
Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer
Molecular markers in bladder cancer
Focal therapy in intermediate- and high-risk prostate cancer
Neoadjuvant therapy in urothelial cancer : New therapies on the horizon
Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers